-
Esomeprazole enteric coated capsule will be officially launched in late June
Time of Update: 2015-04-29
In late June, the national class 4 new drug esomeprazole enteric coated capsule independently developed by Laimei Pharmaceutical Co., Ltd will be officially launched, which means that the new drug res
-
Huaiyu Qingre hemostasis capsule can be used in combination with first-line products
Time of Update: 2015-04-28
Huaiyu Qingre hemostasis capsule, the exclusive Chinese medicine of Ma Yinglong, has been listed in the second half of last year (2014), but the company's personnel said it was inconvenient to disclos
-
Growth hormone water injection, a new biological drug of Anke, is expected to enter the field inspection within this year
Time of Update: 2015-04-28
The growth hormone water injection (i.e recombinant human growth hormone injection) has been progressing smoothly since the application for production approval in August last year, and the company is
-
Advanced biological long-term anti AIDS drug ibovetai holds the mid-term coordination meeting of phase III clinical trials
Time of Update: 2015-04-27
After 12 years of hard research and development, the world's first long-term anti AIDS drug, ibovetai, is expected to complete clinical research and enter the market in 2016 Ibovetai is a long-acting
-
A new Chinese medicine, acoladine, may be a new therapy for drug-resistant prostate cancer
Time of Update: 2015-04-27
Carcinogenesis (if 5.266), an international well-known cancer journal, recently published an article entitled "a new treatment method for prostate cancer: akoladine activates aromatic hydrocarbon rece
-
CDE drug review weekly report (April 19, 2015 to April 25, 2015)
Time of Update: 2015-04-27
Among the 60 drugs that entered the review sequence this week, 56 were chemicals, including 37 new drugs, 15 generic drugs and 4 imported drugs Attention: this week, the drug dotiravir sodium tablet
-
Whether the clinical application of Watson biological class 1 vaccine is suspected or not
Time of Update: 2015-04-27
According to the information on the website of CFDA on April 27, the status of clinical application and review of meningococcal Haemophilus influenzae b polysaccharide conjugate vaccine of class 1 bio
-
Wu Zhong pharmaceutical's class I anticancer drug (Su Qiujia) clinical trial failed for a long time, and shareholders began to fire at the management
Time of Update: 2015-04-25
On April 17, Jiangsu Wuzhong (600200) annual general meeting of shareholders, the company is in clinical trials of a class of original anti-cancer drug research project (Su Qiujia) due to the delay ca
-
Wuxi apptec completed the preclinical research of anti her2-adc
Time of Update: 2015-04-25
In the evening of April 24, it was announced that with the concerted efforts of Zhejiang Pharmaceutical, ambrx Inc and Wuxi Wuxi Wuxi pharmaceutical Kant Biotechnology Co., Ltd (hereinafter referred t
-
Approval for production of "ambrano", a new heavyweight drug of Haizheng pharmaceutical
Time of Update: 2015-04-24
According to the information on CFDA website, the declaration status of "ambano" (recombinant human tumor necrosis factor II receptor antibody fusion protein for injection) of Haizheng Pharmaceutical
-
Six biopharmaceutical listed companies have obtained clinical approval or production approval recently
Time of Update: 2015-04-23
On April 22, it was learned from the State Food and drug administration that six biopharmaceutical listed companies, including shutaishen, Hualan biology and Boya biology, respectively obtained clinic
-
New drug nafeprolol, a class 1.1 drug for asthma and COPD, was accepted by CDE
Time of Update: 2015-04-22
At the same time that the imported COPD drugs are approved by the domestic clinic, the domestic new drug R & D enterprises are not willing to lag behind Naparo, a new 1.1 drug of Shandong Henley Pharm
-
Clinical approval of kangbaoruiadinium bromide, a subsidiary of Wuxi apptec
Time of Update: 2015-04-22
On April 14, 2015, adinium powder inhalant was approved for clinical use in China, and Shanghai kangbaorui medical clinical research Co., Ltd., a subsidiary of Yao mingkant, a cro company, applied Ade
-
Three dimensional structure of key factors in thrombosis determined by Shanghai Pharmaceutical Research Institute for the first time
Time of Update: 2015-04-21
Great breakthrough has been made in the field of structural biology of purinergic receptor p2y1r by Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences: the high-resolution thr
-
CDE drug review weekly report (April 13, 2015 to April 19, 2015)
Time of Update: 2015-04-21
The drugs that enter the approval process this week are chemicals The details are as follows: Daphne hydrobromide sustained-release tablets, raw materials + sustained-release tablets, category 3 + 3 declaration of Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd is the only manufacturer applying for production of this product in China But this week, only one acceptance number is being approved, and it's a preparation What about the raw materials?
-
Sun Hongbin's team of China Pharmaceutical University approved the clinical trial of class 1.1 new antithrombotic drug "Viagra tablet"
Time of Update: 2015-04-21
Sun Hongbin, a distinguished professor of "Yangtze River Scholar" from the Institute of Pharmaceutical Sciences, China Pharmaceutical University, and Jiangsu Weikeli pharmaceutical science and Technol
-
Strengthen the supervision of animal experiment data quality in the UK
Time of Update: 2015-04-21
The UK Research Council and other agencies responsible for the approval and distribution of government research funds jointly issued the latest announcement, saying that they will revise the applicati
-
Shanghai wisechem will present cutting-edge research results at the 2015 annual meeting of the American Association for cancer research
Time of Update: 2015-04-19
As a long-term partner of global pharmaceutical R & D enterprises, chempartner has always adhered to the concept of scientific research as the driving force and technology as the basis Shanghai wisech
-
CDE drug review report in March 2015
Time of Update: 2015-04-17
Guide reading: the application volume of new drugs has decreased compared with the previous two months Guangdong Dongyang tiantini, yinglitini hausen, has obtained the following clinical approval docu
-
Suoyuan bio positioning precision medical guidance clinical "waste" innovative drug research and development and regeneration
Time of Update: 2015-04-16
Suoyuan biological company, a subsidiary of Xianju pharmaceutical, said at the strategic meeting of securities companies that the company positioned precision medicine, guided the research and develop
